Morgan Petronelli

Media expert Paige Velasquez Budde, CEO of Zilker Media, explains the importance of building a brand as a physician, as well as some mistakes to avoid and tips on how to grow and shape your brand.

Entrepix Medical, LLC, launches their new Planatome blade, which has shown in multiple studies to increase wound closure, reduce tissue trauma and strength the wound.

Aesthetic medicine company, Allergan Aesthetics, launches a new brand identity focused on empowering confidence and promoting diversity.

This week’s edition of The Mainstream Patient features stories about snail slime in skincare, how to treat hyperpigmentation, different exfoliation methods, maskne during the fall, plus more.

ICYMI, some of the content featured this week includes articles about antihistamines for alopecia areata, treating pediatric patients with skin of color, topical roflumilast study results, racial disparities in melanoma survival, plus more.

The U.S. FDA has approved to expand the indication for golimumab (SIMPONI ARIA, Janssen Pharmaceutical Companies of Johnson & Johnson) to include it was a treatment for active psoriatic arthritis (PsA) in pediatric patients 2 years and older.

ZILXI (FMX103, VYNE Therapeutics), a 1.5% topical minocycline foam, is now available for prescription for the treatment of inflammatory lesions of rosacea in adult patients.

DefenAge announces the launches of their 6-Week Perfection Neck Cream, designed to improve the appearance of the neck by diminishing fine lines, folds and wrinkles.

Arcutis Biotherapeutics announces topline results from its recent phase 2 clinical study investigating topical roflumilast foam for the treatment of seborrheic dermatitis.

In the final part of our interview with Candrice Heath, M.D., she discusses some of the treatment challenges associated with treating pediatric patients with skin of color and how to overcome these obstacles.

A recent study published in the Journal of the American Academy of Dermatology found positive results when using antihistamines, along with topical corticosteroids and superficial cryotherapy, as a combination treatment for alopecia areata.

In part two of our interview with Candrice Heath, M.D., she explains the most commonly encountered skin conditions when treating young skin of color patients.

Candrice Heath, M.D., shares her tips and tricks for treating young skin of color patients from her presentation at the 2020 Skin of Color Update.

This week’s edition of The Mainstream Patient features stories about vitiligo, turmeric in skincare, how to handle skin exposed to wildfire smoke, plus more.

ICYMI, some of the content featured this week includes articles about how to choose a telemedicine vendor, the launch of an international COVID-19 dermatology registry, a study evaluating dupilumab’s durability versus cyclosporine in patients with atopic dermatitis, plus more.

The latest guidelines for psoriasis from the American Academy of Dermatology and the National Psoriasis Foundation recommend physicians monitor their patients for liver disease when prescribed medication for psoriasis, such as methotrexate.

A study published by the American Society of Laser Medicine and Surgery reveals the efficacy of the 755-nm picosecond laser as a treatment for melasma in Asian women with darker skin types.

Esther Freeman, M.D., details the team effort made by the American Academy of Dermatology’s (AAD) COVID-19 Task Force to launch an international registry documenting skin manifestations in patients diagnosed with or suspected of COVID-19 infection.

A recent article suggests physicians should be on the lookout for various dermatologic manifestations in pediatric patients suspected of having COVID-19.

AVITA Therapeutics has launched a study evaluating their RECELL System as a treatment for stable vitiligo.

With the increase in telemedicine use, physicians can (virtually) meet their patients’ needs now more than ever. However, with this swift increase in telehealth usage, how can physicians choose the best telemedicine vendor for their practice with so many options available?

UCB announces the U.S. Food and Drug Administration and the European Medicines Agency have accepted the Biologics License Application and Marketing Authorization Application for bimekizumab for the treatment of moderate-to-severe plaque psoriasis in adults.

This week’s edition of The Mainstream Patient features stories about dark circles, sun damage on different skin tones, wearing sunscreen with a mask, sleep’s effect on skin health, plus more.

ICYMI, some of the content featured this week includes articles about a new diversity and equity initiative from Skinbetter Science and Allergan Aesthetics, patient sunscreen savviness, skin of color patients lacking in phase 3 psoriasis trials, plus more.

In this episode, Candrice Heath, M.D., sits down to discuss her recent presentation at the 2020 Skin of Color Update about clinical pearls for kids, tweens and teens with skin of color. Dr. Heath also explains the most common skin conditions for this patient group, treatment challenges, and much more.

Merck announces positive results from its phase 2b trial evaluating sonelokinab, an investigational anti-IL-17 A/F nanobody, in adult patients with moderate-to-severe chronic plaque psoriasis.

Allergan Aesthetics and Skinbetter Science announce the launch of The DREAM Initiative, aimed at improving racial diversity and equity in the aesthetics field.

The U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) filing for Sol-Gel’s Epsolay, a 5% microencapsulated benzoyl peroxide cream for the treatment of inflammatory lesions of rosacea or papulopustular rosacea.

Novartis announces their phase 3 study investigating spartalizumab (PDR001) in combination with dabrafenib (Tafinlar) and trametinib (Mekinist) failed to meet its primary endpoint.

This week’s edition of The Mainstream Patient features stories about the difference between sunblock and sunscreen, lip dryness after getting filler, stress and psoriasis, the issues around skin lightening products, plus more.